Monitor for further insider selling in the coming weeks, especially if additional director/executive sales emerge. The post-acquisition selling pattern is not alarming by itself, but sustained selling could signal reduced confidence in near-term integration prospects.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $156.50entry
- T+1 · 6mo ago −0.50%α −1.08% · $155.72
- T+5 · 6mo ago +2.54%α +0.89% · $160.48
- T+20 · 5mo ago +3.27%α +3.44% · $161.62
- T+60 · 3mo ago −1.45%α −4.37% · $154.23
Price Chart
How similar events traded
Executive Summary
Two NBIX directors sold shares totaling ~$40.8M following the closing of the $2.9B Soleno acquisition, representing modest insider selling (0.26% of market cap). The sales coincide with option exercises and may reflect routine portfolio rebalancing rather than a negative business outlook, but the timing post-deal close warrants monitoring.
Key Financial Metrics
Key Facts
- Three directors sold shares: Kevin Gorman ($37.8M), Richard Pops ($2.4M), Leslie Norwalk ($0.6M) between May 12-19, 2026.
- Total insider sales: $40.78M, representing ~0.26% of NBIX's $15.6B market cap.
- Sales occurred shortly after the closing of the $2.9B Soleno Therapeutics acquisition on May 18, 2026.
- All sales were accompanied by concurrent option exercises (non-cash) at lower strike prices.
Financial Impact
$40.78M in insider sales, ~0.26% of market cap
Risk Factors
- Additional insider sales may pressure the stock in the short term.
- Integration of Soleno's VYKAT XR could face commercial or regulatory hurdles.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1779400217159 |
Track record
30 reports on NBIX
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers